nach oben

World Journal of Urology

Erschienen in:

09.02.2018 | Original Article

Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study

verfasst von: Chu-Wen Fang, Cheng-Hsi Liao, Shih-Chi Wu, Chih-Hsin Muo

Erschienen in: World Journal of Urology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Few studies discussed the link between benign prostatic hyperplasia (BPH) and bladder cancer. We performed this cohort study to investigate whether there is an association between BPH and subsequent risk of bladder cancer.

Methods

We identified 35,092 study subjects including 17546 BPH patients and 17546 comparisons from the National Health Insurance database. The comparison cohort was frequency matched with age and index-year. We measured subsequent bladder cancer rates (per 1000 person-years) in two cohorts. Attributable risks (ARs) was calculated based on the bladder cancer rates in two cohorts. The hazard ratios (HRs) and 95% confidence intervals (CIs) for bladder cancer were estimated via Cox proportional hazard regression.

Results

BPH patients had a higher bladder cancer rate than comparisons (AR = 0.81 per 1000 person-years) and exhibited 4.69- and 4.11-fold increases in bladder cancer risk in the crude and adjusted Cox models, respectively (95% CIs = 4.15–6.99 and 2.70–6.26). The AR was highest in patients aged 65–74 years old (AR = 1.33). BPH patients with chronic kidney disease were at an elevated bladder cancer risk. Regarding the association between bladder cancer and transurethral prostatectomy (TURP), BPH patients who underwent TURP were at a higher risk of bladder cancer (AR = 1.69; HR = 6.17, 95% CI = 3.68–10.3) than those who did not (AR = 0.69; HR = 3.73, 95% CI = 2.43–5.74).

Conclusions

In this study, BPH patients were found to have an increased risk of subsequent bladder cancer. Based on the limitations of retrospective nature, further studies are needed.

Auffenberg GB, Helfand BT, McVary KT (2009) Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 36:443–459CrossRefPubMed

Barry MJ, Fowler FJ Jr, Bin L et al (1997) The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 157:10–14CrossRefPubMed

Fong YK, Milani S, Djavan B (2005) Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 15:35–38CrossRefPubMed

Djavan B, Nickel JC, de la Rosette J et al (2002) The urologist view of BPH progression: results of an international survey. Eur Urol 41(5):490–496CrossRefPubMed

Sarma AV, Wei JT (2012) Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med 367(3):248–257CrossRefPubMed

Matsumoto S, Shimizu N, Hanai T, Uemura H, Levin R (2009) Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int 103:1436–1439CrossRefPubMed

Hecht SS (2002) Human urinary carcinogen metabolites: biomarkers for investigating tobacco and cancer. Carcinogenesis 23(6):907–922CrossRefPubMed

Mommsen S, Sell A (1983) Prostatic hypertrophy and venereal disease as possible risk factors in the development of bladder cancer. Urol Res 11(2):49–52CrossRefPubMed

Nakata S, Sato J, Ohtake N et al (1995) Epidemiological study of risk factors for bladder cancer. Hinyokika Kiyo 41(12):969–977PubMed

10.

Greenwald P, Kirmss V, Polan A et al (1974) Cancer of the prostate among men with benign prostatic hyperplasia. J Natl Cancer Inst 53:335–340CrossRefPubMed

11.

Kang D, Chokkalingam AP, Gridley G et al (2007) Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br J Cancer 96(9):1475–1479CrossRefPubMedPubMedCentral

12.

Tseng CH (2013) Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer 13:7CrossRefPubMedPubMedCentral

13.

Dai X, Fang X, Ma Y et al (2016) Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer: a meta-analysis of observational studies. Medicine (Baltim) 95(18):e3493CrossRef

14.

Lin YC, Liang SJ, Liu YH, Hsu WH, Shih CM, Sung FC, Chen W (2012) Tuberculosis as a risk factor for systemic lupus erythematosus: results of a nationwide study in Taiwan. Rheumatol Int 32(6):1669–1673CrossRefPubMed

15.

Sung PS, Yeh CC, Wang LC, Hung PH, Muo CH, Sung FC, Chen CH, Tsai KJ (2017) Increased risk of dementia in patients with non-apnea sleep disorder. Curr Alzheimer Res 14(3):309–316PubMed

16.

Kang JH, Keller JJ, Lin YK, Lin HC (2012) A population-based case-control study on the association between rheumatoid arthritis and deep vein thrombosis. J Vasc Surg 56(6):1642–1648CrossRefPubMed

17.

Tseng CH (2011) Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 54(8):2009–2015CrossRefPubMed

18.

Lo SF, Chang SN, Muo CH, Chen SY, Liao FY, Dee SW, Chen PC, Sung FC (2013) Modest increase in risk of specific types of cancer types in type 2 diabetes mellitus patients. Int J Cancer 132(1):182–188CrossRefPubMed

19.

Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC (2011) Association between smoking and risk of bladder cancer among men and women. JAMA 306(7):737–745CrossRefPubMedPubMedCentral

20.

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234–241CrossRefPubMed

21.

Walker NF, Gan C, Olsburgh J et al (2014) Diagnosis and management of intradiverticular bladder tumours. Nat Rev Urol 11(7):383–390CrossRefPubMed

22.

Michaud DS, Spiegelman D, Clinton SK et al (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340:1390–1397CrossRefPubMed

23.

Jiang X, Castelao JE, Groshen S et al (2008) Water intake and bladder cancer risk in Los Angeles County. Int J Cancer 123:1649–1656CrossRefPubMed

24.

Radosavljević V, Janković S, Marinković J et al (2003) Fluid intake and bladder cancer. A case control study. Neoplasma 50(3):234–238PubMed

25.

Zhou J, Kelsey KT, Giovannucci E et al (2014) Fluid intake and risk of bladder cancer in the Nurses’ Health Studies. Int J Cancer 135(5):1229–1237CrossRefPubMedPubMedCentral

26.

Altieri A, La Vecchia C, Negri E et al (2003) Fluid intake and risk of bladder and other cancers. Eur J Clin Nutr 57(Suppl 2):S59–S68CrossRefPubMed

27.

Zhou J, Smith S, Giovannucci E et al (2012) Reexamination of total fluid intake and bladder cancer in the health professionals follow-up study cohort. Am J Epidemiol 175(7):696–705CrossRefPubMedPubMedCentral

28.

Shariat SF, Milowsky M, Droller MJ (2009) Bladder cancer in the elderly. Urol Oncol. 27(6):653–667CrossRefPubMedPubMedCentral

29.

Taylor JA 3rd, Kuchel GA (2009) Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. Nat Clin Pract Urol 6(3):135–144CrossRefPubMedPubMedCentral

30.

Serrano M, Blasco MA (2007) Cancer and ageing: convergent and divergent mechanisms. Nat Rev Mol Cell Biol 8:715–722CrossRefPubMed

31.

Toren Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448:767–774CrossRefPubMed

32.

Lichtman SM et al (2007) Geriatric oncology: a field coming of age. J Clin Oncol 25:1821–1823CrossRefPubMed

33.

Lynch CF, Cohen MB (1995) Urinary system. Cancer 75:316–329CrossRefPubMed

34.

Perše M, Injac R, Erman A (2013) Oxidative status and lipofuscin accumulation in urothelial cells of bladder in aging mice. PLoS One. 8(3):e59638CrossRefPubMedPubMedCentral

35.

Blagosklonny MV (2005) Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 12(6):592–602CrossRefPubMed

36.

Shahriyari L, Komarova NL (2013) Symmetric vs. asymmetric stem cell divisions: an adaptation against cancer? PLoS One 8(10):e76195CrossRefPubMedPubMedCentral

37.

Hou L, Zhang X, Wang D et al (2012) Environmental chemical exposures and human epigenetics. Int J Epidemiol 41(1):79–105CrossRefPubMed

38.

Wood GA, Korkola JE, Archer MC (2002) Tissue-specific resistance to cancer development in the rat: phenotypes of tumor-modifier genes. Carcinogenesis 23(1):1–9CrossRefPubMed

39.

Rassweiler J, Teber D, Kuntz R et al (2006) Complications of transurethral resection of the prostate (TURP)–incidence, management, and prevention. Eur Urol 50(5):969–979CrossRefPubMed

40.

Yamasaki T, Naganuma T, Iguchi T et al (2011) Association between chronic kidney disease and small residual urine volumes in patients with benign prostatic hyperplasia. Nephrology (Carlton) 16(3):335–339CrossRef

41.

Rule AD, Jacobson DJ, Roberts RO et al (2005) The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 67(6):2376–2382CrossRefPubMed

42.

Chen CH, Shun CT, Huang KH, Huang CY, Yu HJ, Pu YS (2008) Characteristics of female non-muscle-invasive bladder cancer in Taiwan: association with upper tract urothelial carcinoma and end-stage renal disease. Urology. 71:1155–1160CrossRefPubMed

43.

Li CE, Chien CS, Chuang YC et al (2016) Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer. Int Urol Nephrol. 48(6):993–999CrossRefPubMed

44.

Birkeland SA, Lokkegaard H, Storm HH (2000) Cancer risk in patients on dialysis and after renal transplantation. Lancet 355:1886–1887CrossRefPubMed

45.

Kasiske BL, Snyder JJ, Gilbertson DT, Wang C (2004) Cancer after kidney transplantation in the United States. Am J Transplant. 4:905–913CrossRefPubMed

Titel: Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study
verfasst von: Chu-Wen Fang
Cheng-Hsi Liao
Shih-Chi Wu
Chih-Hsin Muo
Publikationsdatum: 09.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2018
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-018-2216-8

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Association of benign prostatic hyperplasia and subsequent risk of bladder cancer: an Asian population cohort study

Abstract

Objectives

Methods

Results

Conclusions

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Prospective randomised controlled trial of written supplement to verbal communication of results to patients at the time of flexible cystoscopy

Magnetic resonance imaging as an adjunct diagnostic tool in computed tomography defined Bosniak IIF–III renal cysts: a multicenter study

Assessment of readability, quality and popularity of online information on ureteral stents

Preoperative chronic kidney disease before radical cystectomy as predictor of oncological outcomes: a pick of the iceberg?

Antimicrobial lubricant reduces rectal bacteria at transrectal prostate biopsy: results from a prospective randomized trial

Modified York Mason technique for repair of iatrogenic recto-urinary fistula: 20 years of the Montsouris experience

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie